Business
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
Development Candidate Targeting IRAK4 Now Progressing Toward Clinical DevelopmentWATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to
About this update from C4 Therapeutics, Inc.
[{"type":"image","alt":"C4 Therapeutics, Inc.","displaySize":"","headline":null,"caption":"C4 Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/octIZ3xbuMh0O2fgF.yqVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85","width":300,"height":45}},"lazy":false},{"type":"text","content":"Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development","length":81,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to explore for therapeutic use in patients with autoimmune diseases.","length":484,"tagName":"p"},{"type":"text","content":"“We are thrilled to see Biogen quickly advance the IRAK4 degrader that resulted from our collaboration toward the clinic in the hopes this molecule may bring a new treatment option to patients with autoimmune disease,” said Paige Mahaney, Ph.D., chief scientific officer of C4 Therapeutics. “Our long-standing collaboration with Biogen helped C4T build and deepen capabilities across our platform as we worked together to develop degraders for a broad range of target classes and therapeutic areas to reach a sizeable number of patients with unmet needs. We look forward to Biogen’s continued progress with BIIB142, as well as the second development candidate delivered under our collaboration.”","length":695,"tagName":"p"},{"type":"text","content":"“Our collaboration with C4 Therapeutics has been both powerful and deeply productive, pairing C4T’s expertise in targeted protein degradation with Biogen’s scientific leadership and drug development capabilities,” said Jane Grogan, Ph.D., head of research at Biogen. “I’m proud that we have advanced this program based on a cutting-edge modality for a disease with high unmet need, and we see great promise in c...